CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Triple therapy for hepatitis C virus (HCV) infection: Eligibility, safety and efficacy in a real world setting
DOI 10.1055/s-0032-1332155
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB Maasoumy, K Port, AA Markova, B Calle Serrano, L Sollik, J Kirschner, C Mix, MP Manns, H Wedemeyer, M Cornberg
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background:HCV protease inhibitors (PIs) Boceprevir and Telaprevir in combination with PEG-Interferon alfa and Ribavirin (P/R) is the new standard of care in the treatment of chronic HCV genotype 1 (GT1) infection. However, not every HCV GT1 infected patient is eligible for P/R/PI. Furthermore phase III studies did not necessarily reflect real world as patients with advanced liver disease or comorbidities were under…
Zitieren
Zitierempfehlung
B Maasoumy, K Port, AA Markova, B Calle Serrano, L Sollik, J Kirschner, C Mix, MP Manns, H Wedemeyer, M Cornberg (2013) Triple therapy for hepatitis C virus (HCV) infection: Eligibility, safety and efficacy in a real world setting. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0032-1332155
Mit CareLit weiterarbeiten